Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

Author： Wang Xinkang Smith Patricia Hsu Mei-Yin Tamasi Joseph Bird Eileen Schumacher William

Publisher： Springer Publishing Company

ISSN： 0929-5305

Source： Journal of Thrombosis and Thrombolysis, Vol.23, Iss.1, 2007-02, pp. : 41-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)

By Bouma B.N. Marx P.F. Mosnier L.O. Meijers J.C.M.

Thrombosis Research, Vol. 101, Iss. 5, 2001-03 ,pp. : 329-354

Elsevier

Access to resources Recommend Favorite

Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

Medical Principles and Practice, Vol. 20, Iss. 4, 2011-05 ,pp. : 332-335

Karger

Access to resources Recommend Favorite

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels

By Ozkan Gulsum

Clinical and Experimental Hypertension, Vol. 35, Iss. 2, 2013-04 ,pp. : 134-140

Informa Healthcare

Access to resources Recommend Favorite

An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis Model *

By Nagashima M. Werner M. Wang M. Zhao L. Light D.R. Pagila R. Morser J. Verhallen P.

Thrombosis Research, Vol. 98, Iss. 4, 2000-05 ,pp. : 333-342

Elsevier

Access to resources Recommend Favorite

Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism

By Erem Cihangir

Endocrine Journal, Vol. 35, Iss. 1, 2009-02 ,pp. : 75-80

Humana Press, Inc

Access to resources Recommend Favorite